INTRODUCTION
Nucleosides traverse a mammalian cell membrane primarily via the equilibrative and\or Na + -dependent concentrative transport processes. The former can be subdivided into nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) components, where NBMPR is a specific inhibitor of equilibrative nucleoside transport. Equilibrative nucleoside transport is present in both normal and neoplastic cells, but the activity is higher in neoplastic cells, with the es component predominating [1] . In contrast, Na + -dependent concentrative nucleoside transport is usually present in normal cells, but either absent or functioning at a very low level in neoplastic cells [1] . Combined with a higher metabolism in neoplastic cells, this might explain why normal cells are able to accumulate intracellular uridine pools that are absent from neoplastic cells [2] .
On differentiation in itro, equilibrative nucleoside transport tends to be down-regulated, whereas the Na + -dependent concentrative nucleoside transport is usually up-regulated. Our previous studies show that when human HL-60 promyelocytic leukaemia cells are induced into monocytic or granulocytic differentiation with PMA or DMSO respectively, a rapid 80-94 % decrease in growth occurs [3] [4] [5] , together with a decrease in the number of es transporter proteins (B max from 198 000 to 12 000 sites per cell [3] and from 280 000 to 9790 sites per cell [5] for monocytic and granulocytic differentiation respectively). At the same time, Na + -dependent concentrative transport affinity for uridine increases (K m from 44 µM to approx. 1 µM) [4, 5] . Further stimulation of DMSO-differentiated HL-60 cells by a chemotactic peptide, Nformylmethionyl-leucylphenylalanine, results in an instantaneous 3-fold increase in V max of the Na + -dependent concentrative transport of uridine [6] . Even in growth-retarded tamoxifentreated MCF-7 cells, an upsurge in the Na + -dependent concenAbbreviations used : es, NBMPR-sensitive equilibrative nucleoside transporter ; ei, NBMPR-insensitive equilibrative nucleoside transporter ; FBS, fetal bovine serum ; HBSS, Hanks balanced salt solution ; NBMPR, nitrobenzylthioinosine. 1 To whom correspondence should be addressed. trative transport of uridine has been reported [7] , where dome formation in cultures points to tamoxifen's role as a differentiation inducer for MCF-7 cells.
In the present study we have found that prolonged exposure of MCF-7 cells to tamoxifen resulted in a decrease in the number of es nucleoside transporters on the cell membrane. A preliminary account of some of the work presented here has been published in abstract form [8] . . 17β-Oestradiol, tamoxifen, NBMPR, nitrobenzylthioguanosine and dipyridamole were obtained from Sigma Chemical (St. Louis, MO, U.S.A.). All other reagents were of A. R. grade. Tamoxifen was dissolved in DMSO and 17β-oestradiol was dissolved in 100 % ethanol. The final concentrations of DMSO and ethanol in the culture medium were always at 0.03 % and 0.1 % (both v\v) respectively.
EXPERIMENTAL

Materials
Cell culture
MCF-7 human breast cancer cells were maintained as a continuous culture in RPMI 1640 medium (Gibco, Gaithersburg, MD, U.S.A.) containing Phenol Red and supplemented with 10 % (v\v) heat-inactivated (50 mC for 30 min) fetal bovine serum (FBS) (Gibco) plus 50 i.u.\ml penicillin and 50 µg\ml strep-tomycin (Sigma). Cells were cultured to near confluency in 50 ml of culture medium in 75 cm# flasks unless stated otherwise in the legends. The culture medium was completely aspirated before cells were harvested via 3-4 min of trypsin treatment [0.05 % trypsin\0.02 % EDTA in 150 mM NaCl\5 mM KCl\0.3 mM potassium phosphate\5.6 mM -glucose\4 mM Hepes (pH 7.4)]. Next, cells were pelleted, suspended in 50 ml of Hanks balanced salt solution (HBSS) and left for 5 min to allow any membranebound tamoxifen to dissociate. This was followed by centrifugation before the final pellet was resuspended in respective buffers. For experiments involving tamoxifen and\or 17β-oestradiol, appropriate amounts of these two compounds were added 2 days after subculture. Ethanol up to a concentration of 0.5 % (v\v) has no apparent effect on the proliferation of MCF-7 cells (results not shown). Complete removal of trypsin was not necessary for cell reattachment.
Determination of cell numbers and viability
Cells were counted after trypsin treatment with the help of an electronic Coulter counter (Coulter Electronics, Luton, Beds., U.K. 
RESULTS
Time course of uridine uptake by MCF-7 cells
The MCF-7 cells tested did not possess the active type of uridine transport requiring the presence of Na + (Figure 1 ). There was no difference in the uptake of 50 µM [$H]uridine for up to 5 min, regardless of whether Na + -containing or Na + -free (choline replacement) HBSS was used as the transport medium. The only uptake component measurable was almost completely abolished by 30 µM dipyridamole, a potent inhibitor of equilibrative transport, in both the presence and the absence of Na + . Although the initial linearity of the transport curve lasted for slightly less than 15 s, all subsequent transport kinetic studies were conducted with a 15 s uptake interval. This was to obtain reasonable signalto-noise ratio. Furthermore the amount of intracellular uridine metabolized at this uptake interval was only about 10 %, as analysed by HPLC (results not shown). This equilibrative nucleoside transport system was next ascertained for its sensitivity towards NBMPR and other inhibitors of nucleoside transport.
Inhibition of equilibrative uridine transport by NBMPR, dipyridamole and dilazep in MCF-7 cells
The concentration responses of MCF-7 cells to the three equilibrative nucleoside transport inhibitors were investigated in the absence of Na + ions. All three transport-inhibition curves were 
biphasic (Figure 2 ). Approx. 70 % of the carrier-mediated [$H]uridine (50 µM) transport activity was inhibited by NBMPR, dipyridamole and dilazep, with IC &! values of 0.1, 1 and 0.1 nM respectively. There was no further inhibition until the concentrations of NBMPR, dipyridamole and dilazep exceeded 0.1, 3 and 0.1 µM respectively. Hence MCF-7 cells were found to possess both the es and ei components of equilibrative uridine transport. These two equilibrative nucleoside transport components were also distinguishable with dipyridamole and dilazep.
Substrate specificity of equilibrative uridine transporter proteins
The substrate specificity of the es and ei components in MCF-7 cells was studied by investigating the effect of uridine uptake inhibition by physiological nucleosides such as adenosine, guanosine, inosine, thymidine and cytidine ( The es and ei components of nucleoside transport in MCF-7 cells apparently exhibited different substrate specificities. In the es component, purine nucleosides were more effective inhibitors of uridine uptake than the pyrimidine nucleosides. The calculated mean K i values were 80p10 (n l 3), 255p60 (n l 3) and 345p60 µM (n l 3), for adenosine, guanosine and inosine respectively. For pyrimidine nucleosides such as thymidine and cytidine, the mean K i values were 495p55 (n l 3) and 660p 120 µM (n l 4) respectively. The ei component, however, seemed to prefer inosine (K i l 75p15 µM; n l 3) and thymidine (K i l 60p1 µM; n l 2) as a substrate. Adenosine (K i l 2610p 1900 µM; n l 3), cytidine (K i 10 mM ; n l 4) and guanosine (K i l 715p120 µM; n l 3) were poorly accepted by this component.
Concentration dependence and temporal effects of tamoxifen on MCF-7 cell growth and NBMPR binding
MCF-7 cells were exposed to various concentrations of tamoxifen for 5 days. The maximum effect of tamoxifen was at 10 µM, which caused a 63 % decrease in cell density ( Figure 3A) , and a 48 % decrease in the number of NBMPR binding sites (from 190 000p2300 to 100 000p20 000 sites per cell) measured with 5 nM [$H]NBMPR ( Figure 3B ). Note that the culture medium used in this experiment contained Phenol Red, which is mildly oestrogenic [11] . The FBS supplement also contains oestrogen at approx. 10 nM. With this huge amount of oestrogen present,
Figure 4 Temporal effects of tamoxifen on cell growth and NBMPR binding
MCF-7 cells were subcultured at an initial density of 2.5i10 4 cells/ml for 2 days before exposure to 10 µM tamoxifen (TMF). The number of specific NBMPR-binding sites (A) and cell density (B) were determined as described in the Experimental section. The numbers of NBMPR-binding sites were determined with a single concentration of tamoxifen at 10 µM was non-cytotoxic to MCF-7 cells for at least 5 days (cell viability more than 90 %). This is in contrast with an earlier report, using cell culture medium free of oestrogens, which cited this concentration of tamoxifen to be cytotoxic [12] . Thus, in subsequent studies, 10 µM tamoxifen was used as it exerted the greatest effect on both growth and NBMPRbinding sites without compromising cell viability at the same time.
Next, MCF-7 cells were exposed to 10 µM tamoxifen for up to 6 days. By day 6 of incubation, the number of NBMPR-binding sites determined with 5 nM [$H]NBMPR had decreased by 47 %, from 220 000p15 000 sites per untreated cell to 117 000p2500 sites per tamoxifen-treated cell ( Figure 4A ). The cell density was decreased by 57 % (Figure 4B ). More than 90 % of the cells were viable throughout the 6 days of incubation. However, to coincide with the exponential phase of growth in control cells, so as to minimize complications arising from cell arrest effects, a 5-day exposure to tamoxifen (10 µM) was employed in subsequent studies.
Effects of tamoxifen on the kinetics of NBMPR equilibrium binding
To determine whether tamoxifen's effect on NBMPR binding was a result of a change in K d or B max , MCF-7 cells were treated with or without 10 µM tamoxifen for 5 days before being harvested for the high affinity [$H]NBMPR-binding assay ( Figure  5 ). Tamoxifen induced a 44 % decrease in B max from 245 000p 18 000 to 136 000p25 000 sites per cell (n l 5; P 0.05). K d values, however, remained relatively unchanged at 0.37p0.05 and 0.45p0.08 nM, for untreated and tamoxifen-treated cells respectively (n l 5; P 0.05).
Effects of tamoxifen on the kinetics of es and ei transport of uridine
The effect of tamoxifen on the es component was investigated via high-affinity NBMPR binding. However, the effect on the ei component could not be determined similarly owing to the absence of a suitable ligand for the latter. However, the effect of tamoxifen on the ei component can be directly studied through tamoxifen's influence on the kinetics of ei uridine transport. Thus MCF-7 cells were treated with or without 10 µM tamoxifen for 5 days and both the es ( Figure 6A ) and ei ( Figure 6B Thus it is shown that tamoxifen could decrease the maximum transport velocity of the es component without any substantial change in its transport affinity for uridine. From the previous section we know that this is a result of fewer es nucleoside transporters and not a decrease in the efficiency of nucleoside translocation, as indicated by the unchanged affinity of the NBMPR-binding sites. The ei component was, in contrast, not susceptible to the down-regulatory effect of tamoxifen. This implied that tamoxifen's effect on the es component is not a non-specific phenomenon. 
Reversal of tamoxifen's effect on growth and NBMPR binding by oestradiol
MCF-7 cell growth increased with increasing concentrations of oestradiol from 0 to 3000 nM in the presence of 10 µM tamoxifen (Table 2 ). It is evident that oestradiol concentrations between 10 and 3000 nM were capable of reversing the anti-proliferative effect of tamoxifen. Cell density was increased in the presence of 100 nM oestradiol, to that of the tamoxifen-untreated control. A similar profile was observed with changes in the number of NBMPR-binding sites in the presence of various concentrations of oestradiol. Apparently, 100 nM oestradiol was sufficient to reverse the decrease in NBMPR-binding sites resulting from treatment with tamoxifen, almost to that of the tamoxifen-untreated control. Tamoxifen-untreated MCF-7 cells did not respond in terms of growth and NBMPR binding to the same concentration range of oestradiol (results not shown).
Table 2 Reversal of effect of tamoxifen on growth and NBMPR binding by oestradiol
MCF-7 cells were cultured in six-well plates at an initial density of 4i10 3 cells/ml for 2 days, after which 10 µM tamoxifen and graded concentrations of oestradiol were added. After 5 days of incubation, the cell density and the number of specific NBMPR-binding sites were measured as described in the Experimental section. respectively. This next portion of transport activity is categorized as ei transport. Similar biphasic inhibition curves of uridine transport for these inhibitors have also previously been observed in human HL-60 leukaemia cells [4] , murine Sp2\0-Ag14 myeloma [13] , murine L1210 leukaemia cells [14] and guinea-pig synaptosomes [15] . However, the inhibition curves for dipyridamole in others such as the rat synaptosomes [9] , Chinese hamster ovary cells, murine P388 leukaemia cells and a few other mammalian cell lines [16] were monophasic, even though the inhibitions by NBMPR were biphasic. These results suggest that the two forms of equilibrative nucleoside transporters distinguishable with NBMPR are probably not distinguishable with dipyridamole in some cells and tissues in certain species. The substrate specificities of the es and ei components in MCF-7 cells were distinctly different. Apparently the es component preferred purine nucleosides (K i from 80 to 345 µM) as substrates more than pyrimidine nucleosides (K i from 495 to 660 µM). The K i values obtained were very similar to those reported for HL-60 cells [4] , where K i values of purine nucleosides in inhibiting uridine uptake ranged from 170 to 700 µM and those for pyrimidine nucleosides from 510 to 1430 µM. In murine Sp2\0-Ag14 myeloma cells [13] , however, there was no distinct preference of the es component for either purine or pyrimidine nucleosides. In contrast, the ei component in MCF-7 cells seemed more sensitive to nucleosides without an amine side group, such as inosine and thymidine. This is not the case in guinea-pig synaptosomes [15] , which showed that the transport affinities for most physiological nucleosides were generally higher for the es than for the ei component. Nevertheless, the present observation is similar to that in HL-60 cells [4] and murine Sp2\0-Ag14 myeloma cells [13] , except that adenosine is a good substrate for the ei component in HL-60 and Sp2\0-Ag14 cells.
The presence of the es component in MCF-7 cells enabled us to monitor and compare its changes in these cells with the highaffinity [$H]NBMPR-binding assay. During prolonged exposure to tamoxifen, an anti-proliferative effect was observed in MCF-7 cells as expected. The approx. 60 % decrease in MCF-7 cell growth observed is an improvement over those previously reported, where a 40-55 % decrease in growth was observed with a similar concentration of tamoxifen [12, [17] [18] [19] , albeit under slightly different cell culture conditions [5 % (v\v) dextrancharcoal-treated FBS instead of the 10 % (v\v) native FBS used in this study]. Concurrent with retardation in cell growth, the total number of NBMPR-binding sites decreased by 44 %. The V max of es transport of uridine in these cells also decreased by 61 % with relatively unaltered uridine transport affinity and NBMPR-binding affinity. Tamoxifen has been shown to decrease membrane fluidity in MCF-7 cells. However, the effect on es transporter was not a non-specific membrane phenomenon, because the ei component of uridine transport remained unaffected by tamoxifen. Moreover, Trypan Blue exclusion assays of tamoxifen-treated cells consistently revealed a cell viability above 90 %. Control experiments also showed that the vehicle (0.03 % DMSO) did not contribute any apparent effects to cell growth. In our recent paper, tamoxifen was found to inhibit uridine uptake and NBMPR binding [20] . However, this does not pose as a problem in this study. Our control experiments have shown that the cell-washing method adopted and described in the Experimental section was effective. Hence there was no significant amount of tamoxifen left from the culture medium to interfere with NBMPR binding or uridine uptake.
An almost completely reversed condition of sustained growth was observed in tamoxifen-treated MCF-7 cells exposed to 100 nM oestradiol. Cell growth was increased from 48 000 to 133 000 cells\ml, close to the control value of 134 000 cells\ml. Other oestradiol-reversible effects of tamoxifen have been documented earlier in tamoxifen's inhibition of cell growth [12, 19, 21] , although some of the reversals were partial, in contrast with this study. By using an oestrogen receptor enzymic immunoassay, we have found that incubation of MCF-7 cells with 10 µM tamoxifen for 5 days led to a 1.3-fold increase in the number of oestrogen receptors per cell compared with untreated control cells (results not shown). Hence the cell model that we were working with has increased the number of available oestrogen receptors in the presence of tamoxifen. This might perhaps be an attempt to compensate for the inhibitory effects of tamoxifen. With oestradiol counteracting tamoxifen's anti-proliferative effect, the number of NBMPR-binding sites also reverted from 134 000 to 261 000 sites per cell, close to the control level of 245 000 sites per cell. This positive correlation of NBMPR-sensitive nucleoside transporter proteins with proliferation has also been observed in HL-60 cells induced to differentiate [3] [4] [5] . Further supportive evidence of this positive correlation can be found in our recent studies where, in i o, the numbers of NBMPR binding sites were found to be significantly higher in freshly harvested human breast, colorectal, liver and stomach tumour tissues than in their normal counterparts from the same patient [22] . In conclusion, the decrease in es nucleoside transporter proteins in tamoxifentreated MCF-7 cells was found to occur via a mechanism that can be interfered with by oestradiol.
